TORONTO – NOV 11, 2021 – On November 7th, during the 4th China International Import Expo, Geneseeq was invited by Takeda Pharmaceutical (TSE:4502/NYSE:TAK)(“Takeda”) to participate in the launch ceremony of the Takeda Lung Cancer Diagnosis and Treatment Alliance to sign off on the two companies’ strategic partnership. The companies jointly stated that they will actively respond to the overall requirements of China’s “Precision Medicine Plan”, advance lung cancer precision medicine development, standardize precision diagnostics in clinical care, and improve patient access to personalized medicine.

On the same morning, Geneseeq and AstraZeneca (“AstraZeneca”) (LSE/STO/Nasdaq: AZN) united with six other industry partners to establish Astrazeneca’s Lung Cancer Early Detection Alliance. Ms. Shanshan Yang, the Head of the Early Detection Program of Geneseeq, was invited to speak at the launching ceremony: “Geneseeq is willing to work with all members of the Lung Cancer Early Detection Alliance to combine resources and expertise to empower the development and application of lung cancer early screening and early diagnosis technologies.”